



INSURANCE AND FINANCIAL ASSISTANCE QUICK GUIDE

Once you've made the decision with your doctor to start on Evrysdi, Genentech is dedicated to helping you start and stay on therapy. **This guide provides information on:**



Insurance coverage



MySMA Support



Financial support options

Visit www.Evrysdi.com/insuranceguide to download the Insurance and Financial Assistance Quick Guide

What is Evrysdi?

Evrysdi is a prescription medicine used to treat spinal muscular atrophy (SMA) in children and adults.

Important Safety Information

- **Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you:**
 - are pregnant or plan to become pregnant, as Evrysdi may harm your unborn baby. Ask your healthcare provider for advice before taking this medicine

These are not all the possible side effects of Evrysdi. Please see full [Prescribing Information](#) and additional Important Safety Information on page 6.

MySMA Support team is here for you

The MySMA Support team is available to answer your questions and provide product education, including how to take Evrysdi. They can also help you understand your insurance coverage and refer you to appropriate financial assistance options to start and stay on Evrysdi. MySMA Support does not provide medical advice and is not a substitute for your medical team. Your healthcare provider should always be your main resource for any questions about your health and medical care.

Contact MySMA Support at 1-833-387-9734 (Monday-Friday, 9 AM to 8 PM ET)

Partnership and Access Liaison (PAL)



A PAL is the local, main point of contact from Genentech who supports people living with spinal muscular atrophy (SMA). PALs are here to answer questions about Evrysdi, and refer you to helpful resources. PALs can also help you understand your insurance and financial support options. A PAL is not a part of your medical team and is not a substitute for your healthcare provider. PALs do not provide medical advice. Your healthcare provider should always be your main resource for any questions about your health and medical care.

A PAL is available in-person, over the phone, and online, and will reach out after you enroll in MySMA Support. **Please answer if you get a call from an unknown number—it may be a PAL.**

Case Manager (CM)



A Case Manager partners closely with PALs and healthcare providers to help people living with SMA understand the health insurance process and identify potential financial support options for Genentech's approved products.

A PAL will be your primary contact for Genentech, but a CM may answer the phone if you call the help line.

Specialty Pharmacy (SP)



An SP prepares and ships Evrysdi directly to you each month. Although the SP is not a part of Genentech, it is an important part of the MySMA Support team.*

Contact MySMA Support to coordinate the preparation and delivery of your medicine with the specialty pharmacy

Call: 1-833-387-9734

Patients who are hospitalized may, in some instances, receive Evrysdi while in the hospital through CuraScript Specialty Distribution (CuraScript SD) Services.

*Specialty pharmacies are not part of Genentech and maintain independence in their operations and in their role as a healthcare provider.

Please see full [Prescribing Information](#) and additional Important Safety Information on page 6.



There are financial support options available for Evrydsi

Your insurance coverage affects the type of support you may be eligible for:



Commercial/private health insurance



Government-funded health insurance
(Medicaid/Medicare)



No insurance or Evrydsi is not covered



Evrydsi Co-pay Program*

- With the Evrydsi Co-pay Program, eligible patients with commercial insurance could pay as little as \$0 per 30-day supply of Evrydsi. The rest of your co-pay or co-insurance is covered, up to \$25,000 in assistance per calendar year.

*The Co-pay Program is valid ONLY for patients with commercial (private or non-governmental) insurance who have a valid prescription for a Food and Drug Administration (FDA)-approved indication of a Genentech medicine. Patients using Medicare, Medicaid or any other federal or state government program (collectively, "Government Programs") to pay for their Genentech medicine are not eligible. Under the Program, the patient may pay a co-pay. The final amount owed by a patient may be as little as \$0 for the Genentech medicine (see Program specific details available at the Program website). The total patient out-of-pocket cost is dependent on the patient's health insurance plan. The Program assists with the cost of the Genentech medicine only. It does not assist with the cost of other medicines, procedures or office visit fees. After reaching the maximum annual Program benefit amount, the patient will be responsible for all remaining out-of-pocket expenses. The Program benefit amount cannot exceed the patient's out-of-pocket expenses for the cost associated with the Genentech medicine. All participants are responsible for reporting the receipt of all Program benefits as required by any insurer or by law. The Program is only valid in the United States and U.S. Territories, is void where prohibited by law and shall follow state restrictions in relation to AB-rated generic equivalents (e.g., MA, CA) where applicable. No party may seek reimbursement for all or any part of the benefit received through the Program. The Program is intended for the patient. The value of the Program is intended exclusively for the benefit of the patient. The funds made available through the Program may only be used to reduce the out-of-pocket costs for the patient enrolled in the Program. The Program is not intended for the benefit of third parties, including without limitation third party payers, pharmacy benefit managers, or their agents. If Genentech determines that a third party has implemented a program that adjusts patient cost-sharing obligations based on the availability of support under the Program and/or excludes the assistance provided under the Program from counting towards the patient's deductible or out-of-pocket cost limitations, Genentech may impose a per fill cap on the cost-sharing assistance available under the Program. Submission of true and accurate information is a requirement for eligibility and Genentech reserves the right to disqualify patients who do not comply from Genentech programs. Genentech reserves the right to rescind, revoke or amend the Program without notice at any time. Additional terms and conditions apply. Please visit the Co-pay Program website for the full list of Terms and Conditions.



Referrals to independent co-pay foundations†

- If you need help with the co-pay for your Evrydsi, a Case Manager can refer you to an independent co-pay assistance foundation



†Independent co-pay assistance foundations have their own rules for eligibility. Genentech has no involvement or influence in independent foundation decision-making or eligibility criteria and does not know if a foundation will be able to help you. We can only refer you to a foundation that supports your disease state. Genentech does not endorse or show preference for any particular foundation. The foundations we refer you to may not be the only ones that might be able to help you.



The Genentech Patient Foundation‡

- The Genentech Patient Foundation gives free Evrydsi to people who do not have insurance coverage or who have financial concerns and meet eligibility criteria



‡If you have health insurance, you should try to get other types of financial assistance, if available. You also need to meet income requirements. If you do not have insurance, or if your insurance does not cover your Genentech medicine, you must meet a different set of income requirements. Genentech reserves the right to modify or discontinue the program at any time and to verify the accuracy of the information submitted.




Please see full [Prescribing Information](#) and additional [Important Safety Information](#) on page 6.



A sample Evrysdi access journey

This is a sample path to accessing Evrysdi. Individual paths may vary.



MySMA Support



Doctor's office



Specialty Pharmacy

*Enrollment in MySMA Support through the Evrysdi Start Form is mandatory to receive assistance through the program. Participation in MySMA Support is not necessary to receive treatment with Evrysdi.

Please see full [Prescribing Information](#) and additional [Important Safety Information](#) on page 6.



Breaking down insurance terms, step by step

The MySMA Support Team can help you understand:

- If your health insurance plan covers Evrysdi
 - If more information is needed before your plan will pay for your medicine. This is called a **prior authorization (PA)**
 - The expected out-of-pocket costs, including deductibles and co-pays
 - You and your doctor are responsible for completing and submitting all required paperwork to your health insurance plan. Genentech cannot guarantee your plan will cover any treatments

If a PA and/or appeal is necessary, MySMA Support can help:

- Identify the required PA form and documents for submission for the health insurance plan
 - Provide general resources to help you and your doctor file an **appeal** or PA
- Please note: Genentech cannot complete or submit an appeal for you or your doctor's office.

If your health insurance plan doesn't cover Evrysdi, your doctor can appeal on your behalf

- An appeal is submitted by your doctor's office. While health insurance plans vary, there may be more than one level of appeal
- MySMA Support can provide general resources to assist your doctor's office with an appeal

Your health insurance plan may require reauthorization

- Your health insurance plan might only cover your Genentech medicine for a certain period of time (usually 6 to 12 months). If you still need the Genentech medicine after this time, your doctor's office will have to do a **reauthorization**. An approved reauthorization can provide continued coverage for your medicine so you don't miss any doses
- Record your experience with SMA. It may be helpful to keep notes around any changes you may experience. Keeping this type of information may be helpful in conversations with your doctor, and for submission of any reauthorizations

What is Low Income Subsidy (LIS)/Extra Help?

- The LIS program, commonly known as Extra Help, may provide financial assistance to eligible low-income Medicare Part D beneficiaries to help cover prescription drug costs

To see if you're eligible, please visit: <https://www.cms.gov/files/document/lis-memo.pdf>

- Eligible Medicare beneficiaries may receive a full or partial subsidy based on certain income and resource requirements. Income requirements are determined annually and are based on the federal poverty line²
 - For more information about this program, contact Medicare at 1-800-633-4227 or visit <https://www.medicare.gov>

Please see full [Prescribing Information](#) and additional Important Safety Information on page 6.



Important Safety Information (cont'd)

- **Before taking Evrysdi, tell your healthcare provider about all of your medical conditions, including if you (cont'd):**
 - are a woman who can become pregnant:
 - Before you start your treatment with Evrysdi, your healthcare provider may test you for pregnancy
 - Talk to your healthcare provider about birth control methods that may be right for you. Use birth control while on treatment and for at least 1 month after stopping Evrysdi
 - **Pregnancy Registry.** There is a pregnancy registry for women who take Evrysdi during pregnancy. The purpose of this registry is to collect information about the health of the pregnant woman and her baby. If you are pregnant or become pregnant while receiving Evrysdi, tell your healthcare provider right away. Talk to your healthcare provider about registering with the Evrysdi Pregnancy Registry. Your healthcare provider can enroll you in this registry or you can enroll by calling 1-833-760-1098 or visiting www.evrysdipregnancyregistry.com
 - are an adult male. Evrysdi may affect a man's ability to have children (fertility). Ask a healthcare provider for advice before taking this medicine
 - are breastfeeding or plan to breastfeed. It is not known if Evrysdi passes into breast milk and may harm your baby
- **Tell your healthcare provider about all the medicines you take**
- You should receive Evrysdi from the pharmacy as a liquid. If the medicine in the bottle is a powder, **do not use it.** Contact your pharmacist for a replacement
- Avoid getting Evrysdi on your skin or in your eyes. If Evrysdi gets on your skin, wash the area with soap and water. If Evrysdi gets in your eyes, rinse your eyes with water
- **The most common side effects of Evrysdi include:**
 - For later-onset SMA:
 - fever
 - diarrhea
 - rash
 - For infantile-onset SMA:
 - fever
 - diarrhea
 - rash
 - runny nose, sneezing and sore throat (upper respiratory infection)
 - lung infection (lower respiratory infection)
 - constipation
 - vomiting
 - cough

These are not all of the possible side effects of Evrysdi. For more information on the risk and benefits profile of Evrysdi, ask your healthcare provider or pharmacist.

You may report side effects to the FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. You may also report side effects to Genentech at 1-888-835-2555.

Please see full Prescribing Information for additional Important Safety Information.

References: 1. Risdiplam (EVRYSDI®) Prescribing Information. South San Francisco, CA; Genentech, Inc; 2022.
2. Shapiro J. 2022 Resource and cost-sharing limits for Low-Income Subsidy (LIS). Centers for Medicare & Medicaid Services. Published October 25, 2021. Accessed June 14, 2022. <https://www.cms.gov/files/document/lis-memo.pdf>

Genentech
A Member of the Roche Group

© 2024 Genentech USA, Inc. All rights reserved.
M-US-00016498(v3.0) 06/24

